Impact Partnership Wealth LLC Raises Stock Position in Cencora, Inc. (NYSE:COR)

Impact Partnership Wealth LLC grew its stake in Cencora, Inc. (NYSE:COR) by 15.5% during the 4th quarter, HoldingsChannel reports. The fund owned 2,358 shares of the company’s stock after purchasing an additional 316 shares during the quarter. Impact Partnership Wealth LLC’s holdings in Cencora were worth $530,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Insight Wealth Strategies LLC grew its position in Cencora by 124.6% during the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock valued at $4,549,000 after purchasing an additional 11,232 shares during the last quarter. Cerity Partners LLC grew its holdings in shares of Cencora by 10.1% during the third quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock valued at $8,881,000 after buying an additional 3,610 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. lifted its position in Cencora by 71.1% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock valued at $1,583,000 after acquiring an additional 2,928 shares in the last quarter. Portfolio Design Labs LLC purchased a new stake in Cencora during the 3rd quarter valued at $1,404,000. Finally, Mackenzie Financial Corp increased its holdings in Cencora by 9.9% in the 2nd quarter. Mackenzie Financial Corp now owns 81,001 shares of the company’s stock worth $18,250,000 after buying an additional 7,266 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

COR has been the topic of a number of research reports. Leerink Partners dropped their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Barclays upped their price objective on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Mizuho started coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price for the company. Wells Fargo & Company reduced their price target on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a report on Friday, December 13th. Finally, UBS Group raised their price objective on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $275.60.

Cencora Stock Performance

COR stock opened at $247.84 on Friday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The firm has a market cap of $47.90 billion, a price-to-earnings ratio of 33.00, a PEG ratio of 1.54 and a beta of 0.49. The firm has a 50-day simple moving average of $237.26 and a two-hundred day simple moving average of $234.40. Cencora, Inc. has a one year low of $214.77 and a one year high of $253.27.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a $0.55 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. Cencora’s dividend payout ratio is presently 29.29%.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares of the company’s stock, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 73,187 shares of company stock valued at $17,790,912. Corporate insiders own 15.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.